Home

Early Implementation of THAM for ICP Control: Therapeutic Hypothermia Avoidance and Reduction in Hypertonics/Hyperosmotics

Show simple item record

dc.contributor.author Zeiler, F. A.
dc.contributor.author Gillman, L. M.
dc.contributor.author Teitelbaum, J.
dc.contributor.author West, M.
dc.date.accessioned 2015-05-14T16:08:13Z
dc.date.available 2015-05-14T16:08:13Z
dc.date.issued 2014-12-4
dc.identifier.citation F. A. Zeiler, L. M. Gillman, J. Teitelbaum, and M. West, “Early Implementation of THAM for ICP Control: Therapeutic Hypothermia Avoidance and Reduction in Hypertonics/Hyperosmotics,” Case Reports in Critical Care, vol. 2014, Article ID 139342, 4 pages, 2014. doi:10.1155/2014/139342
dc.identifier.uri http://dx.doi.org/10.1155/2014/139342
dc.identifier.uri http://hdl.handle.net/1993/30471
dc.description.abstract Background. Tromethamine (THAM) has been demonstrated to reduce intracranial pressure (ICP). Early consideration for THAM may reduce the need for other measures for ICP control. Objective. To describe 4 cases of early THAM therapy for ICP control and highlight the potential to avoid TH and paralytics and achieve reduction in sedation and hypertonic/hyperosmotic agent requirements. Methods. We reviewed the charts of 4 patients treated with early THAM for ICP control. Results. We identified 2 patients with aneurysmal subarachnoid hemorrhage (SAH) and 2 with traumatic brain injury (TBI) receiving early THAM for ICP control. The mean time to initiation of THAM therapy was 1.8 days, with a mean duration of 5.3 days. In all patients, after 6 to 12 hours of THAM administration, ICP stability was achieved, with reduction in requirements for hypertonic saline and hyperosmotic agents. There was a relative reduction in mean hourly hypertonic saline requirements of 89.1%, 96.1%, 82.4%, and 97.0% for cases 1, 2, 3, and 4, respectively, comparing pre- to post-THAM administration. Mannitol, therapeutic hypothermia, and paralytics were avoided in all patients. Conclusions. Early administration of THAM for ICP control could potentially lead to the avoidance of other ICP directed therapies. Prospective studies of early THAM administration are warranted.
dc.title Early Implementation of THAM for ICP Control: Therapeutic Hypothermia Avoidance and Reduction in Hypertonics/Hyperosmotics
dc.type Journal Article
dc.language.rfc3066 en
dc.description.version Peer Reviewed
dc.rights.holder Copyright © 2014 F. A. Zeiler et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
dc.date.updated 2015-03-29T13:26:19Z


Files in this item

This item appears in the following Collection(s)

  • Research Publications [1145]
    This collection contains full text research publications authored or co-authored by University of Manitoba researchers.

Show simple item record

View Statistics